Table 1. Clinical characteristics of the study subjects and laboratory measurements.
Subject ID | Sex | Age | KPS Score | CDC Status | Plasma viral load (RNA copies/ml) | CD4+ T-cell count (cells/µl) | ΔViral load | ΔCD4+ T-cell count | |||||
TEnrol | TInter | TFinal | TEnrol | TInter | TFinal | ||||||||
204 | F | 26 | 100 | A | 5.70 | 5.75 | 5.76 | 253 | 217 | 157 | 0.064 | −96 | |
258 | F | 30 | 100 | A | 5.76 | 5.74 | 5.73 | 503 | 334 | 305 | 0.025 | −198 | |
455 | F | 44 | 70 | A | 5.75 | 5.74 | 5.80 | 157 | 313 | 141 | 0.048 | −172 | |
513 | F | 46 | 100 | B | 5.70 | 5.66 | 5.76 | 640 | 624 | 216 | 0.06 | −424 | |
550 | F | 31 | 100 | B | 5.66 | 5.65 | 5.77 | 164 | 126 | 35 | 0.11 | −129 | |
574 | F | 27 | 100 | A | 5.67 | 5.68 | 5.68 | 241 | 281 | 172 | 0.009 | −69 | |
805 | F | 40 | 100 | A | 5.61 | 5.57 | N/A | 341 | 143 | N/A | −0.034 | −198 | |
858 | F | 27 | 90 | B | 5.69 | 5.65 | 5.66 | 320 | 280 | 250 | −0.027 | −70 | |
1109 | F | 26 | 100 | A | 5.54 | 5.59 | 5.67 | 367 | 402 | 169 | 0.125 | −198 | |
1114 | F | 35 | 100 | B | 5.63 | 5.70 | 5.74 | 284 | 220 | 149 | 0.118 | −135 | |
1136 | F | 29 | 100 | A | 5.70 | 5.75 | 5.78 | 231 | 78 | 97 | 0.08 | −134 | |
1375 | F | 22 | 100 | B | 5.71 | 5.71 | 5.70 | 464 | 349 | 171 | −0.006 | −293 | |
1408 | F | 27 | 100 | A | 5.72 | 5.77 | N/A | 392 | 198 | N/A | 0.05 | −197 | |
1441 | M | 28 | 100 | B | 5.68 | 5.73 | 5.73 | 208 | 170 | 111 | 0.04 | −97 | |
1503 | F | 29 | 100 | A | 5.73 | 5.69 | 5.71 | 396 | 168 | 259 | −0.016 | −137 | |
1554 | F | 28 | 50 | C | 5.73 | 5.71 | 5.69 | 342 | 237 | 177 | −0.036 | −165 | |
1684 | F | 40 | 100 | A | 5.73 | 5.69 | 5.72 | 208 | 138 | 141 | −0.006 | −67 | |
1689 | M | 34 | 100 | A | 5.63 | 5.67 | 5.63 | 229 | 157 | 138 | 0.005 | −91 | |
1854 | F | 31 | 100 | A | 5.61 | 5.67 | 5.67 | 435 | 279 | 272 | 0.001 | −163 | |
2042 | F | 41 | 100 | A | 5.73 | 5.75 | 5.71 | 278 | 5 | 10 | −0.015 | −277 | |
2253 | F | 42 | 100 | B | 5.69 | 5.77 | 5.79 | 278 | 147 | 129 | 0.09 | −149 |
Age, Karnofsky scale of performance (KPS) score and Centers for Disease Control (CDC) status were determined at study enrolment. Plasma viral load values are shown as log10. Plasma viral load and CD4+ T-cell counts are shown at the times of study enrolment (Tenrol), approximately 1 year later (Tinter), and approximately 3 years after enrolment (Tfinal). The change in viral load (Δviral load) and CD4+ T-cell count (Δ CD4+ T-cell count) over the study period is also shown. F, female; M, male; N/A, not available.